| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10792-014-9901-4 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s10792-014-9901-4 |
| P698 | PubMed publication ID | 24442759 |
| P50 | author | Senol Kobak | Q90014142 |
| P2093 | author name string | Hülya Devecı | |
| P2860 | cites work | Improvement of lacrimal function by topical application of CyA in murine models of Sjögren's syndrome | Q31776007 |
| Schirmer test and break-up time of tear film in normal subjects | Q33477001 | ||
| The diagnosis and management of dry eye: a twenty-five-year review | Q34048201 | ||
| Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. | Q34436347 | ||
| A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada | Q34441489 | ||
| Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group | Q34523084 | ||
| Evaluation of patients with dry eye for presence of underlying Sjögren syndrome. | Q37219304 | ||
| Clinical Review: Topical Ophthalmic Use of Cyclosporin A | Q37782084 | ||
| Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group | Q40765221 | ||
| Important concepts for treating ocular surface and tear disorders | Q41664259 | ||
| Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
| Evaluation of topical cyclosporine for the treatment of dry eye disease | Q44443222 | ||
| [0.05% cyclosporine a for treatment of chronic severe ocular surface disease]. | Q45928199 | ||
| Prolonged survival of corneal allografts in rabbits treated with cyclosporin A | Q66706219 | ||
| Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis | Q67938095 | ||
| Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy | Q69288448 | ||
| Effect of cyclosporin A on the T-effector and T-suppressor cell response in contact sensitivity | Q70021784 | ||
| Sjögren's syndrome (Sicca syndrome): current issues | Q71131300 | ||
| Relapsing Wegener's granulomatosis: successful treatment with cyclosporin-A | Q71457761 | ||
| Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome | Q72418731 | ||
| Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine | Q77729873 | ||
| Cyclosporin A increases tear fluid secretion via release of sensory neurotransmitters and muscarinic pathway in mice | Q77753274 | ||
| P433 | issue | 5 | |
| P921 | main subject | cyclosporine | Q367700 |
| eye disease | Q3041498 | ||
| P304 | page(s) | 1043-1048 | |
| P577 | publication date | 2014-01-19 | |
| P1433 | published in | International Ophthalmology | Q15763839 |
| P1476 | title | The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome. | |
| P478 | volume | 34 |
| Q37719148 | A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye. |
| Q57378488 | Current and emerging therapy of dry eye disease. Part A: pharmacological modalities |
| Q35570541 | Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence |
| Q91934535 | Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases |
| Q47639135 | Dry eye syndrome: developments and lifitegrast in perspective |
| Q41592241 | Effect of Systemic Infliximab Therapy in Patients with Sjögren's Syndrome |
| Q89536542 | Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies |
| Q52608828 | Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye. |
| Q91905513 | Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease |
| Q38584878 | Recommendations for the treatment of Sjögren's syndrome |
| Q33825538 | Safety and efficacy of cyclosporine in the treatment of chronic dry eye. |
| Q55970269 | The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome |
| Q57045256 | The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial |
| Q26822610 | Therapeutic Strategies to Treat Dry Eye in an Aging Population |
| Q90093016 | Topical cyclosporine A therapy for dry eye syndrome |
Search more.